Clinical comparison · Gut / anti-inflammatory
KPV vs BPC-157
KPV is an alpha-MSH-derived anti-inflammatory tripeptide. BPC-157 is the general soft-tissue and GI healing peptide.
Attribute
KPV
BPC-157
Mechanism
Alpha-MSH C-terminal tripeptide; anti-inflammatory and gut-mucosal healing effects.
Angiogenic pentadecapeptide; VEGFR-2 signaling and fibroblast migration for soft-tissue repair.
Standard dosing
250–500 mcg SC or oral daily.
500 mcg SC twice daily loading, then once daily 4–6 weeks.
Indications
- IBD adjunct
- Skin inflammation
- GI mucosal repair
- Tendonitis / tendinopathy
- Ligament sprains
- GI mucosal inflammation
Strengths
- Oral bioavailability
- Anti-inflammatory without immunosuppression
- Excellent GI + soft-tissue coverage
- Local injection near injury site possible
Cautions
- Emerging clinical data
- Compounded 503A only
- Pause 48h around surgery
- Avoid in active malignancy
FAQs
- Can KPV be dosed orally?
- Yes. Oral bioavailability is one of KPV's key advantages for GI-targeted protocols.
- Can they be combined for gut protocols?
- Yes. KPV for inflammatory modulation + BPC-157 for mucosal repair is a common integrative combination.